Cargando…
Allogeneic transplantation for high-risk chronic lymphocytic leukemia—a summary of a 16-year experience
In the pathway inhibitor era, the number of allogeneic stem cell transplantation (ASCT) for chronic lymphocytic leukemia (CLL) continues to decrease and this approach should be offered only after careful risk-benefit assessment. Nevertheless, ASCT still remains only curative therapeutic modality for...
Autores principales: | Helbig, Grzegorz, Spałek, Adrianna, Wieczorkiewicz-Kabut, Agata, Markiewicz, Mirosław, Kopera, Małgorzata, Zielińska, Patrycja, Woźniczka, Krzysztof, Kopińska, Anna, Grygoruk-Wiśniowska, Iwona, Koclęga, Anna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511342/ https://www.ncbi.nlm.nih.gov/pubmed/30919074 http://dx.doi.org/10.1007/s00277-019-03679-x |
Ejemplares similares
-
Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis
por: Helbig, Grzegorz, et al.
Publicado: (2019) -
Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation
por: Helbig, Grzegorz, et al.
Publicado: (2020) -
Room for Improvement: A 20-Year Single Center Experience with Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes
por: Duda, Katarzyna, et al.
Publicado: (2021) -
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
por: Spałek, Adrianna, et al.
Publicado: (2022) -
Allogeneic hematopoietic stem cell transplantation remains a feasible approach for elderly with acute myeloid leukemia: a 10-year experience
por: Duda, Katarzyna, et al.
Publicado: (2023)